QUE Oncology

QUE Oncology is a clinical stage company dedicated to developing drugs that address large unmet medical needs. The company's lead drug program, Q 122, is specifically focused on treating hot flashes in breast cancer patients and survivors who are undergoing endocrine therapy. Clinical studies have demonstrated that Q 122 can be safely administered, with over 60 patients and healthy volunteers having participated in these studies. Currently, QUE Oncology is conducting a double-blinded, placebo-controlled Phase 2 study to further evaluate the efficacy of Q 122 in this patient population.

QUE Oncology operates with a lean organizational structure, supported by a core team of experts with extensive experience in drug development. The company also collaborates with key consultants and clinicians who bring significant expertise in pharmaceutical drug research and development. This approach allows QUE Oncology to leverage the best experts on a global scale.

The company primarily serves breast cancer patients and survivors who are experiencing hot flashes as a side effect of their hormonal therapy. QUE Oncology operates in the pharmaceutical and biotechnology market, focusing on drug development and clinical trials. The business model involves advancing its drug candidates through clinical trials to demonstrate safety and efficacy, with the ultimate goal of obtaining regulatory approval and commercializing the drugs. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of approved drugs.

Keywords: clinical stage, drug development, breast cancer, hot flashes, endocrine therapy, Q 122, Phase 2 study, pharmaceutical research, safety profile, global experts.